Phibro Animal Health Corporation PAHC
$ 23.47
0.34%
Quarterly report 2024-Q3
added 11-06-2024
Phibro Animal Health Corporation Balance Sheet 2011-2024 | PAHC
Annual Balance Sheet Phibro Animal Health Corporation
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
276 M | 205 M | -15.6 M | 338 M | 269 M | 283 M | 257 M | 319 M | 260 M | 278 M | 338 M | 296 M | - |
Long Term Debt |
312 M | 273 M | 28 M | 368 M | 314 M | 300 M | 307 M | 350 M | 287 M | 286 M | 366 M | 345 M | - |
Long Term Debt Current |
6.05 M | 6.05 M | 6.62 M | 6.44 M | - | - | 6.25 M | 2.8 M | 2.81 M | 2.97 M | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 356 M | 344 M | 356 M | 411 M | 352 M | 345 M | 428 M | 403 M | - |
Total Current Liabilities |
176 M | 191 M | 164 M | 157 M | 154 M | 143 M | 116 M | 109 M | 111 M | 112 M | - | - | - |
Total Liabilities |
689 M | 669 M | 603 M | 596 M | 511 M | 487 M | 472 M | 520 M | 464 M | 457 M | 543 M | 529 M | - |
Deferred Revenue |
370 K | 822 K | 1.56 M | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
261 M | 248 M | 218 M | 183 M | 169 M | 132 M | 82.8 M | 34 M | -37 M | -97.2 M | -94.1 M | -116 M | - |
Total Assets |
971 M | 932 M | 841 M | 784 M | 727 M | 672 M | 623 M | 610 M | 493 M | 472 M | 474 M | 441 M | - |
Cash and Cash Equivalents |
41.3 M | 74.2 M | 50.2 M | 36.3 M | 57.6 M | 29.2 M | 56.1 M | 33.6 M | 29.2 M | 11.8 M | 27.4 M | 53.9 M | - |
Book Value |
283 M | 262 M | 239 M | 188 M | 216 M | 185 M | 151 M | 90.5 M | 29.6 M | 15.1 M | -68.9 M | -88.2 M | - |
Total Shareholders Equity |
283 M | 262 M | 239 M | 188 M | 216 M | 185 M | 151 M | 90.5 M | 29.6 M | 15.1 M | -68.9 M | -88.2 M | - |
All numbers in USD currency
Quarterly Balance Sheet Phibro Animal Health Corporation
2024-Q3 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
288 M | 291 M | 298 M | 305 M | 273 M | 277 M | 281 M | 273 M | 292 M | 293 M | 295 M | 297 M | 297 M | 209 M | 213 M | 218 M | 218 M | 208 M | 213 M | 218 M | 218 M | 224 M | 227 M | 230 M | 230 M | 236 M | 239 M | 242 M | 242 M | 277 M | 278 M | 278 M | 278 M | 282 M | 283 M | 284 M | 284 M | 285 M | 286 M | 286 M | 298 M | - | 332 M | 298 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
708 M | 709 M | 702 M | 691 M | 693 M | 693 M | 686 M | 669 M | 649 M | 610 M | 603 M | 603 M | 603 M | 590 M | 597 M | 596 M | 596 M | 571 M | 589 M | 511 M | 511 M | 492 M | 486 M | 487 M | 487 M | 495 M | 502 M | 472 M | 472 M | 480 M | 496 M | 517 M | 517 M | 468 M | 471 M | 464 M | 464 M | 442 M | 449 M | 457 M | 457 M | - | 543 M | 543 M | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | 508 K | 448 K | 458 K | 822 K | 1.38 M | 1.68 M | 1.4 M | 1.56 M | 1.56 M | 1.87 M | 1.2 M | 1.11 M | 1.11 M | 1.08 M | 1 M | 965 K | 927 K | 1.47 M | 778 K | 508 K | 508 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
246 M | 248 M | 244 M | 248 M | 254 M | 249 M | 247 M | 248 M | 245 M | 232 M | 220 M | 218 M | 218 M | 198 M | 191 M | 183 M | 183 M | 174 M | 167 M | 169 M | 169 M | 155 M | 145 M | 132 M | 132 M | 97.7 M | 94.7 M | 82.8 M | 82.8 M | 51.7 M | 42.2 M | 34 M | 34 M | 8.05 M | -18.2 M | -37 M | -37 M | -64.1 M | -78.3 M | -61.4 M | -76.8 M | - | -94.1 M | -94.1 M | - | - | - | - | - | - | - | - | - |
Total Assets |
966 M | 979 M | 973 M | 965 M | 965 M | 962 M | 948 M | 932 M | 916 M | 849 M | 836 M | 841 M | 841 M | 804 M | 790 M | 784 M | 784 M | 788 M | 795 M | 727 M | 727 M | 697 M | 678 M | 672 M | 672 M | 663 M | 671 M | 623 M | 623 M | 592 M | 598 M | 608 M | 608 M | 521 M | 493 M | 493 M | 493 M | 468 M | 471 M | 472 M | 472 M | - | 474 M | 474 M | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
51.8 M | 50.2 M | 33 M | 43.2 M | 37.2 M | 68.4 M | 76.3 M | 74.2 M | 70.7 M | 63.4 M | 41.2 M | 50.2 M | 50.2 M | 34.5 M | 31 M | 36.3 M | 31 M | 26.2 M | 54.9 M | 26.2 M | 54.9 M | 31.3 M | 25.9 M | 31.3 M | 25.9 M | 40.2 M | 62.1 M | 40.2 M | 62.1 M | 39.2 M | 37.4 M | 39.2 M | 37.4 M | 25.4 M | 31.8 M | 25.4 M | 31.8 M | 20.7 M | 19.7 M | 20.7 M | 19.7 M | 30.5 M | 36.9 M | 27.4 M | 28.3 M | - | - | 53.9 M | - | - | - | 48.6 M | - |
Book Value |
259 M | 270 M | 271 M | 273 M | 272 M | 268 M | 263 M | 262 M | 267 M | 239 M | 233 M | 239 M | 239 M | 213 M | 192 M | 188 M | 188 M | 217 M | 207 M | 216 M | 216 M | 205 M | 192 M | 185 M | 185 M | 168 M | 169 M | 151 M | 151 M | 113 M | 102 M | 90.5 M | 90.5 M | 53.3 M | 22.6 M | 29.6 M | 29.6 M | 26 M | 21.6 M | 15.1 M | 15.1 M | - | -68.9 M | -68.9 M | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
259 M | 270 M | 271 M | 273 M | 272 M | 268 M | 263 M | 262 M | 267 M | 239 M | 233 M | 239 M | 233 M | 213 M | 213 M | 213 M | 192 M | 217 M | 217 M | 217 M | 207 M | 205 M | 205 M | 205 M | 192 M | 168 M | 169 M | 168 M | 169 M | 113 M | 102 M | 90.5 M | 90.5 M | 53.3 M | 22.6 M | 29.6 M | 29.6 M | 26 M | 21.6 M | 26 M | 21.6 M | - | -68.9 M | -68.9 M | - | - | - | -88.2 M | - | - | - | -69.1 M | - |
All numbers in USD currency